Pelvic inflammatory disease develops when lower genital tract organisms ascend and trigger upper tract infection. Systematic reviews associate 78 percent of cases with sexually transmitted pathogens or bacterial vaginosis related polymicrobial infection. Figures on prevalence, risk factors, treatment response, and costs document the resulting burden, including chronic pelvic pain in 17 percent of women and tubal factor infertility in 13.8 percent.
Key Takeaways
- 17% of women with PID develop chronic pelvic pain
- About 85% of salpingitis (inflammation of the fallopian tubes) is caused by sexually transmitted infections (including chlamydia and gonorrhea), which are major causes of PID
- Bacterial vaginosis is present in a substantial proportion of PID cases (commonly reported around 30–50% in clinical studies)
- Smoking is associated with increased risk of PID; one large cohort study reported a 2.0-fold increased risk among current smokers
- Age 15–24 accounts for the highest incidence of chlamydia and gonorrhea in the United States, which are key PID causes
- 78% of PID cases in a systematic review were associated with sexually transmitted pathogens (chlamydia/gonorrhea) and/or BV-associated polymicrobial infection
- 50% of untreated chlamydia infections in women resolve spontaneously within 1 year, leaving a non-trivial fraction that can progress to PID
- 10%–20% of women with untreated gonorrhea develop PID (systematic review range)
- 30%–50% of women with PID have concurrent bacterial vaginosis on evaluation
- Nearly all cases of PID involve an ascent of lower genital tract organisms; polymicrobial infection is reported in a majority of clinical PID cohorts
- 55% of women with PID have mixed anaerobic/aerobic genital tract organisms detected in endometrial fluid or upper genital tract samples
- 75% of PID-associated infertility risk is mediated by tubal factor damage following infection/inflammation
- 6%–10% of women with a history of PID develop ectopic pregnancy
- 13.8% of women with prior PID experience tubal factor infertility (systematic review estimate)
- In a US claims analysis, women with PID had substantially higher annual health expenditures than women without PID (median expenditure multiple reported)
Most PID stems from sexually transmitted infections or BV, and early treatment helps prevent chronic pain, infertility, and ectopic pregnancy.
Related reading
01 · Category
Treatment Efficacy6 stats
01
Ceftriaxone plus doxycycline-based regimens achieve clinical cure in ~90% of outpatient PID cases in clinical trials/observational series (cure rate reported)
02
Alternative regimens for mild-to-moderate PID show comparable clinical response rates to standard regimens in randomized trials (response percent ranges reported)
03
Tubo-ovarian abscess requiring drainage occurs in a minority of TOA patients; one large series reports ~25% undergoing drainage or surgical intervention
04
Mortality from PID/TOA is rare in modern cohorts; one tertiary-care series reported a case-fatality rate below 1%
05
Rehospitalization for complications after PID is uncommon; claims-based studies report readmission rates in low single digits within 30–90 days
06
Chronic pelvic pain risk after PID increases with number of PID episodes; observational studies report higher rates with recurrent PID (percent per episode reported)
Interpretation
Treatment Efficacy Interpretation
Across outpatient and milder-to-moderate PID care, treatment regimens including ceftriaxone plus doxycycline achieve clinical cure in about 90% of cases, and serious outcomes remain relatively uncommon, with drainage needed for only around 25% of tubo-ovarian abscess patients and mortality below 1% in modern cohorts, supporting strong overall treatment efficacy in the available data.
More related reading
02 · Category
Outcomes4 stats
01
75% of PID-associated infertility risk is mediated by tubal factor damage following infection/inflammation
02
6%–10% of women with a history of PID develop ectopic pregnancy
03
13.8% of women with prior PID experience tubal factor infertility (systematic review estimate)
04
4% of women with PID progress to tubo-ovarian abscess (TOA) in follow-up in population-based studies
Interpretation
Outcomes Interpretation
Looking at outcomes, PID is strongly linked to long-term reproductive harm with tubal factor damage driving about 75% of infertility risk and systematic reviews estimating tubal factor infertility in 13.8% of women, alongside additional serious complications like ectopic pregnancy at 6% to 10% and progression to tubo-ovarian abscess in 4%.
More related reading
03 · Category
Burden & Costs4 stats
01
In a US claims analysis, women with PID had substantially higher annual health expenditures than women without PID (median expenditure multiple reported)
02
Inpatient encounters for PID represent a minority of total PID episodes but account for a disproportionate share of direct medical spending (claims-based analyses)
03
The global economic burden attributable to chlamydia/gonorrhea complications (including PID sequelae) is estimated in the billions of US dollars annually (WHO/partner burden analysis)
04
In US emergency department data, PID accounts for an estimated ~0.2% of gynecologic ED visits (syndromic billing/encounter analyses)
Interpretation
Burden & Costs Interpretation
Although inpatient stays make up only a minority of pelvic inflammatory disease episodes, they drive a disproportionate share of direct medical spending, underscoring that the greatest burden and costs come from the most resource intensive cases rather than the sheer number of diagnoses.
04 · Category
Prevention & Treatment4 stats
01
Partner notification and expedited partner therapy reduce reinfection rates for chlamydia and can reduce downstream PID risk (evidence synthesis reports effect size as risk ratio)
02
Expedited partner therapy has been associated with lower persistent/recurrent chlamydia compared with standard partner referral in randomized trials (risk reduction reported)
03
Adherence to recommended PID antibiotic regimens is associated with improved clinical resolution rates (meta-analysis reports absolute differences)
04
Bacterial vaginosis treatment reduces recurrence of BV-associated dysbiosis, which can lower risk of subsequent upper genital tract infection in longitudinal studies (risk reduction reported)
Interpretation
Prevention & Treatment Interpretation
Prevention and treatment efforts that tackle infections early and improve follow through matter most, because partner notification and expedited partner therapy lower reinfection of chlamydia and can reduce downstream PID risk, while better adherence to recommended PID antibiotic regimens and effective treatment of bacterial vaginosis are linked with higher resolution and fewer recurrences.
More related reading
05 · Category
Causation And Risk Factors3 stats
01
About 85% of salpingitis (inflammation of the fallopian tubes) is caused by sexually transmitted infections (including chlamydia and gonorrhea), which are major causes of PID
02
Bacterial vaginosis is present in a substantial proportion of PID cases (commonly reported around 30–50% in clinical studies)
03
Smoking is associated with increased risk of PID; one large cohort study reported a 2.0-fold increased risk among current smokers
Interpretation
Causation And Risk Factors Interpretation
Under the Causation And Risk Factors category, the strongest takeaway is that sexually transmitted infections drive most PID cases with about 85% of salpingitis linked to infections like chlamydia and gonorrhea, while additional contributors such as bacterial vaginosis in roughly 30 to 50% of cases and a 2.0 fold higher risk in current smokers show how both microbial imbalance and lifestyle risk can stack the odds.
More related reading
06 · Category
Industry Overview8 stats
01
78% of PID cases in a systematic review were associated with sexually transmitted pathogens (chlamydia/gonorrhea) and/or BV-associated polymicrobial infection
02
50% of untreated chlamydia infections in women resolve spontaneously within 1 year, leaving a non-trivial fraction that can progress to PID
03
10%–20% of women with untreated gonorrhea develop PID (systematic review range)
04
30%–50% of women with PID have concurrent bacterial vaginosis on evaluation
05
Nearly all cases of PID involve an ascent of lower genital tract organisms; polymicrobial infection is reported in a majority of clinical PID cohorts
06
55% of women with PID have mixed anaerobic/aerobic genital tract organisms detected in endometrial fluid or upper genital tract samples
07
17% of women with PID develop chronic pelvic pain
08
Age 15–24 accounts for the highest incidence of chlamydia and gonorrhea in the United States, which are key PID causes
Interpretation
Industry Overview Interpretation
Industry-wide, PID is strongly tied to sexually transmitted and mixed genital tract infections, with 78% of cases linked to chlamydia or gonorrhea and/or BV, and about 55% showing mixed anaerobic and aerobic organisms in upper genital tract samples.
report visual · Breakdown
Key PID outcomes & downstream complications
Clinical cure is high, while severe downstream outcomes like mortality are rare; infertility and ectopic pregnancy are important longer-term risks.
90%
Ceftriaxone plus doxycycline-based regimens achieve clinical cure in ~90% of outpatient PID cases in clinical trials/obs
10%
10%–20% of women with untreated gonorrhea develop PID (systematic review range)
source-verifiedsciencedirect.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Afolabi. (2026, February 13). Pelvic Inflammatory Disease Statistics. Gitnux. https://gitnux.org/pelvic-inflammatory-disease-statistics
MLA
Marcus Afolabi. "Pelvic Inflammatory Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pelvic-inflammatory-disease-statistics.
Chicago
Marcus Afolabi. 2026. "Pelvic Inflammatory Disease Statistics." Gitnux. https://gitnux.org/pelvic-inflammatory-disease-statistics.
Sources & references
29 datasets cited across this report · attribution is report-level
+13 additional datasets cited (not shown individually)